114.66
price down icon0.95%   -1.10
pre-market  Vorhandelsmarkt:  113.71   -0.95   -0.83%
loading
Schlusskurs vom Vortag:
$115.76
Offen:
$113.85
24-Stunden-Volumen:
1.52M
Relative Volume:
0.98
Marktkapitalisierung:
$5.63B
Einnahmen:
$4.06B
Nettoeinkommen (Verlust:
$413.08M
KGV:
14.31
EPS:
8.01
Netto-Cashflow:
$560.48M
1W Leistung:
+8.12%
1M Leistung:
-28.94%
6M Leistung:
-37.04%
1J Leistung:
-49.67%
1-Tages-Spanne:
Value
$112.12
$115.25
1-Wochen-Bereich:
Value
$99.80
$116.06
52-Wochen-Spanne:
Value
$91.86
$254.15

Charles River Laboratories International Inc Stock (CRL) Company Profile

Name
Firmenname
Charles River Laboratories International Inc
Name
Telefon
781-222-6000
Name
Adresse
251 BALLARDVALE ST, WILMINGTON, MA
Name
Mitarbeiter
20,100
Name
Twitter
@criverlabs
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
CRL's Discussions on Twitter

Vergleichen Sie CRL mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Diagnostics & Research icon
CRL
Charles River Laboratories International Inc
114.66 5.63B 4.06B 413.08M 560.48M 8.01
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
424.24 159.25B 42.90B 6.52B 6.72B 17.05
Diagnostics & Research icon
DHR
Danaher Corp
197.14 132.37B 23.82B 3.77B 4.90B 5.15
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
437.44 32.95B 3.90B 887.87M 798.08M 10.67
Diagnostics & Research icon
A
Agilent Technologies Inc
106.28 28.58B 6.53B 1.26B 1.31B 4.35
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
150.28 24.90B 15.41B 1.37B 2.11B 7.50

Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-21 Herabstufung Goldman Buy → Neutral
2025-03-04 Hochstufung Citigroup Sell → Neutral
2025-03-03 Hochstufung Redburn Atlantic Sell → Neutral
2025-01-22 Herabstufung William Blair Outperform → Mkt Perform
2025-01-17 Herabstufung UBS Buy → Neutral
2024-11-18 Herabstufung CLSA Hold → Underperform
2024-11-07 Hochstufung CLSA Underperform → Hold
2024-10-23 Eingeleitet CLSA Underperform
2024-10-14 Eingeleitet Redburn Atlantic Sell
2024-10-07 Herabstufung Evercore ISI Outperform → In-line
2024-10-02 Herabstufung BofA Securities Buy → Neutral
2024-10-01 Herabstufung Citigroup Neutral → Sell
2024-08-08 Herabstufung JP Morgan Overweight → Neutral
2024-08-08 Herabstufung Robert W. Baird Outperform → Neutral
2024-06-28 Herabstufung Argus Buy → Hold
2024-06-07 Eingeleitet Mizuho Neutral
2024-06-06 Eingeleitet Goldman Buy
2024-02-15 Herabstufung Guggenheim Buy → Neutral
2023-09-13 Eingeleitet TD Cowen Market Perform
2023-07-10 Herabstufung Citigroup Buy → Neutral
2023-02-23 Hochstufung Guggenheim Neutral → Buy
2023-01-12 Herabstufung Jefferies Buy → Hold
2022-09-30 Hochstufung Jefferies Hold → Buy
2022-08-25 Eingeleitet Credit Suisse Outperform
2022-08-04 Herabstufung Morgan Stanley Overweight → Equal-Weight
2022-05-24 Eingeleitet Guggenheim Neutral
2022-04-25 Herabstufung Jefferies Buy → Hold
2022-04-07 Eingeleitet Stephens Overweight
2022-02-17 Bestätigt BofA Securities Buy
2022-02-17 Hochstufung Citigroup Neutral → Buy
2022-02-17 Bestätigt Deutsche Bank Buy
2022-02-17 Bestätigt Morgan Stanley Overweight
2022-02-17 Bestätigt UBS Buy
2021-08-05 Fortgesetzt Credit Suisse Neutral
2020-12-16 Herabstufung Citigroup Buy → Neutral
2020-09-10 Hochstufung Jefferies Hold → Buy
2020-07-01 Hochstufung BofA Securities Neutral → Buy
2020-05-13 Hochstufung UBS Neutral → Buy
2020-04-21 Herabstufung Jefferies Buy → Hold
2020-03-27 Hochstufung Morgan Stanley Equal-Weight → Overweight
2020-03-02 Eingeleitet Deutsche Bank Buy
2020-02-18 Hochstufung Wolfe Research Peer Perform → Outperform
2020-01-10 Hochstufung Goldman Neutral → Buy
2020-01-08 Eingeleitet Wells Fargo Overweight
2020-01-07 Eingeleitet Citigroup Buy
2019-10-18 Herabstufung BofA/Merrill Buy → Neutral
2019-06-10 Eingeleitet SVB Leerink Outperform
2019-04-30 Fortgesetzt Evercore ISI Outperform
2018-12-14 Eingeleitet Deutsche Bank Buy
2018-10-09 Eingeleitet UBS Neutral
2018-08-23 Hochstufung Raymond James Mkt Perform → Outperform
2018-07-17 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2018-06-15 Hochstufung KeyBanc Capital Mkts Sector Weight → Overweight
2018-02-14 Hochstufung SunTrust Hold → Buy
Alle ansehen

Charles River Laboratories International Inc Aktie (CRL) Neueste Nachrichten

pulisher
Apr 27, 2025

Should Weakness in Charles River Laboratories International, Inc.'s (NYSE:CRL) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials? - simplywall.st

Apr 27, 2025
pulisher
Apr 25, 2025

Cell and Gene Therapy Manufacturing Quality Control Market - openPR.com

Apr 25, 2025
pulisher
Apr 24, 2025

Animal Model Market Is Booming Worldwide 2025-2032 | Charles River Laboratories International - openPR.com

Apr 24, 2025
pulisher
Apr 23, 2025

Mice Model Market Seeking Excellent Growth | Charles River, Taconic Biosciences, The Jackson Laboratory - openPR.com

Apr 23, 2025
pulisher
Apr 22, 2025

High Content Screening and Imaging Market Set for 8.4% CAGR Through 2029 - GlobeNewswire Inc.

Apr 22, 2025
pulisher
Apr 22, 2025

Radiopharmaceutical Preclinical CRO Market With In-Detailed - openPR.com

Apr 22, 2025
pulisher
Apr 22, 2025

Upslope Capital Management Sold Charles River (CRL) Due to Thesis Break - MSN

Apr 22, 2025
pulisher
Apr 22, 2025

U.S. Formulation Development Outsourcing Market is Set - openPR.com

Apr 22, 2025
pulisher
Apr 22, 2025

Charles River Leverages Advanced Technology to Expedite Oncology Drug Discovery and Development - Business Wire

Apr 22, 2025
pulisher
Apr 22, 2025

Charles River Laboratories Announces Third-Quarter 2024 Results - ADVFN

Apr 22, 2025
pulisher
Apr 21, 2025

1,000 monkeys in limbo, some stranded in Frederick, Maryland after shipments from Asia - KFOX

Apr 21, 2025
pulisher
Apr 21, 2025

Jefferies Adjusts Price Target on Charles River Laboratories International to $100 From $169, Maintains Hold Rating - marketscreener.com

Apr 21, 2025
pulisher
Apr 18, 2025

According to the Latest Report: Dermatology CRO Market - openPR.com

Apr 18, 2025
pulisher
Apr 17, 2025

Charles River Laboratories International, Inc. (CRL): Among Mid-Cap Stocks Insiders Were Buying in Q1 2025 - MSN

Apr 17, 2025
pulisher
Apr 17, 2025

20 Mid-Cap Stocks Insiders Were Buying in Q1 2025 - Insider Monkey

Apr 17, 2025
pulisher
Apr 17, 2025

Ecotoxicology Market Detailed in New Research Report By 2032| Charles River Laboratories International - openPR.com

Apr 17, 2025
pulisher
Apr 17, 2025

Baird Adjusts Price Target on Charles River Laboratories International to $118 From $101, Keeps Neutral Rating - marketscreener.com

Apr 17, 2025
pulisher
Apr 17, 2025

Charles River (CRL) Receives Price Target Boost from Baird Analyst | CRL Stock News - GuruFocus

Apr 17, 2025
pulisher
Apr 17, 2025

Charles River (CRL) Receives Price Target Boost from Baird Analy - GuruFocus

Apr 17, 2025
pulisher
Apr 16, 2025

The 2 Worst Performing S&P 500 Stocks YTD: Buy, Sell, or Avoid? - Benzinga

Apr 16, 2025
pulisher
Apr 15, 2025

Charles River Laboratories Schedules First-Quarter 2025 Earnings Release and Conference Call | CRL Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Charles River Labs Earnings: Key Q1 2025 Results Coming May 7What to Watch - Stock Titan

Apr 15, 2025
pulisher
Apr 15, 2025

Strength Seen in Charles River (CRL): Can Its 6.9% Jump Turn into More Strength? - Yahoo

Apr 15, 2025
pulisher
Apr 15, 2025

Charles River (CRL) Price Target Reduced Amid Challenges in Life Sciences Sector | CRL Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

US Stocks Climb With Strong Performances From Real Estate And Utilities - Finimize

Apr 15, 2025
pulisher
Apr 15, 2025

US Markets Climb As Sectors Shine With Solid Gains - Finimize

Apr 15, 2025
pulisher
Apr 14, 2025

Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MSN

Apr 14, 2025
pulisher
Apr 14, 2025

TD Cowen Adjusts Charles River Laboratories International's PT to $105 From $179, Keeps Hold Rating - MarketScreener

Apr 14, 2025
pulisher
Apr 14, 2025

Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing - Benzinga

Apr 14, 2025
pulisher
Apr 13, 2025

Charles River & Valo Health's Logica Identifies New Lupus Drug Candidate - MSN

Apr 13, 2025
pulisher
Apr 12, 2025

Charles River Gets Hit By The FDA, Too Early To Bet On A Comeback - Seeking Alpha

Apr 12, 2025
pulisher
Apr 11, 2025

Charles River Faces Significant Regulatory And Macro Pressures (NYSE:CRL) - Seeking Alpha

Apr 11, 2025
pulisher
Apr 11, 2025

Charles River (CRL) Faces Uncertainty with FDA's Shift from Animal Testing | CRL Stock News - GuruFocus

Apr 11, 2025
pulisher
Apr 11, 2025

Wall Street Rebounds, JPMorgan Jumps On Strong Q1 Earnings: What's Driving Markets Friday? - Benzinga

Apr 11, 2025
pulisher
Apr 11, 2025

Baird Adjusts PT on Charles River Laboratories International to $101 From $155, Keeps Neutral Rating - MarketScreener

Apr 11, 2025
pulisher
Apr 11, 2025

Deutsche Bank Adjusts Price Target on Charles River Laboratories International to $140 From $210 - MarketScreener

Apr 11, 2025
pulisher
Apr 11, 2025

What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday? - Benzinga

Apr 11, 2025
pulisher
Apr 11, 2025

Charles River (CRL) Faces Uncertainty with FDA's Shift on Animal Testing | CRL Stock News - GuruFocus

Apr 11, 2025
pulisher
Apr 11, 2025

FDA's Shift in Testing Requirements Poses Challenge for Charles River (CRL) | CRL Stock News - GuruFocus

Apr 11, 2025
pulisher
Apr 11, 2025

Why Charles River Laboratories International, Inc. (CRL) Went Down On Thursday? - Insider Monkey

Apr 11, 2025
pulisher
Apr 11, 2025

Charles River Laboratories International Inc (CRL) Stock Price D - GuruFocus

Apr 11, 2025
pulisher
Apr 11, 2025

Charles River Labs Stock (CRL) Crashes 28% as FDA Signals End of Animal Testing Era - TipRanks

Apr 11, 2025
pulisher
Apr 10, 2025

Charles River: Putting FVE Under Review After FDA Announces Plans to Phase Out Animal Testing - Morningstar

Apr 10, 2025
pulisher
Apr 10, 2025

Charles River Laboratories (CRL) Faces Impact from FDA's Shift A - GuruFocus

Apr 10, 2025
pulisher
Apr 10, 2025

Inotiv and Charles River stock tumble as FDA moves away from animal testing - Investing.com Canada

Apr 10, 2025
pulisher
Apr 10, 2025

Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Apr 10, 2025
pulisher
Apr 10, 2025

Charles River Labs stock tumbles as FDA shifts from animal testing - Investing.com Canada

Apr 10, 2025
pulisher
Apr 10, 2025

FDA Shifts Away from Animal Testing, Charles River (CRL) Shares Could Be Impacted | CRL Stock News - GuruFocus

Apr 10, 2025
pulisher
Apr 10, 2025

FDA to phase out animal testing requirement, adopt AI methods - Seeking Alpha

Apr 10, 2025

Finanzdaten der Charles River Laboratories International Inc-Aktie (CRL)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
diagnostics_research LH
$228.31
price down icon 0.12%
diagnostics_research DGX
$173.76
price down icon 1.20%
$153.79
price down icon 0.45%
diagnostics_research WAT
$337.89
price down icon 0.82%
diagnostics_research MTD
$1,061.79
price down icon 1.23%
diagnostics_research IQV
$150.28
price down icon 0.27%
Kapitalisierung:     |  Volumen (24h):